Phase II study supports potential for Genentech’s Tecentriq® (Atezolizumab) plus Avastin®
Genentech announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma. February 17, 2017